The results showed that the NF-κB activators LPS and TNF-α promoted and the inhibitors bay11-7082 and CAPE repressed NF-κB-driven transcriptional activity dose-dependently in both LN229 and U251 cell lines (Fig. S1a, b), validating the ability of our luciferase reporter gene assay to monitor NF-κB activity in glioma cell lines. This evidence concerns the gene SMC2 and glioma.